# ZYMEWORKS INC. (ZYME) FY2026 Q2 P&L / Income Statement

- Company: ZYMEWORKS INC. (ZYME)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-06, accession number 0001937653-26-000047
- Page: https://plicit.ai/financials/zyme/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/zyme-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Partner

Income statement for 2026-04-01 through 2026-06-30. View: Partner. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Research and development collaborations**: 4,590,000 US dollars
- **Total operating expenses**: 46,770,000 US dollars
- **Loss from operations**: negative 42,180,000 US dollars
- **Other income (expense), net (calculated)**: negative 3,112,000 US dollars
- **(Loss) income before income taxes**: negative 45,292,000 US dollars
- **Income tax recovery (expense)**: negative 273,000 US dollars
- **Net (loss) income**: negative 45,019,000 US dollars
- **Jazz - Development support payments**: 291,000 US dollars
- **Jazz - Drug supply for ongoing studies**: 791,000 US dollars
- **Jazz - Other drug supply**: 45,000 US dollars
- **Jazz - Royalties**: 1,589,000 US dollars
- **BeOne - Drug supply**: 1,664,000 US dollars
- **BeOne - Royalties**: 210,000 US dollars
- **Research and development**: 27,435,000 US dollars
- **General and administrative**: 19,335,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.